von Willebrand factor and soluble E-selectin in hyperlipidaemia: Relationship to lipids and vascular disease

American Journal of Hematology

Volumn 55, Issue 1, 1997, Pages 15-23

  Blann, Andrew D ^a   Davis, Alison ^b   Miller, J Paul ^b   McCollum, Charles N ^b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Atherosclerosis; Cholesterol; Endothelial cells; HDL cholesterol; LDL cholesterol; Soluble E selectin; Triglycerides, Lp(a); von Willebrand factor

Indexed keywords

CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; ARTERIOSCLEROSIS; BLOOD PRESSURE; CASE-CONTROL STUDIES; DIETARY FATS; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; TIME FACTORS; TRIGLYCERIDES; VON WILLEBRAND FACTOR;

EID: 0030972090     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199705)55:1<15::AID-AJH3>3.0.CO;2-6     Document Type: Article

References (51)

1. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:801-809, 1993.
2. Mera SL: Atherosclerosis and coronary heart disease. Br J Biomed Sci 50:235-248, 1993.
3. Stamler J, Wentworth D, Neaton JD for the MRFIT Research Group: Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? J Am Med Assoc 256:2823-2828, 1986.
4. Steinberg D: The cholesterol controversy is over: Why did it take so long? Circulation 80:1070-1078, 1989.
5. Gordon T, Kannel WB, Castelli WB, Dawber TR: Lipoproteins, cardiovascular disease and death. The Framingham Study. Arch Intern Med 141:1128-1131, 1981.
6. Goldbourt U, Holtzman E, Neifeld HN: Total and high density lipoprotein cholesterol in the serum and risk of mortality: Evidence for a threshold effect. Br Med J 290:515-519, 1985.
7. Austin M: Plasma triglycerides and coronary heart disease. Arterio Thromb 11:901-903, 1991.
8. Scanu AM, Fless GM: Lipoprotein (a): Heterogeneity and biological relevance. J Clin Invest 85:1709-1715, 1990.
9. Rhoads GC, Dahlen G, Berg K, Morton NE, Dannenberg AL: Lp(a) lipoprotein as a risk factor for myocardial infarction. J Am Med Assoc 256:2540-2544, 1986.
10. Pearson JD: Markers of endothelial perturbation and damage. Br J Rheum 32:651-652, 1993.
11. Blann AD: von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci 50:125-134, 1993.
12. Blann AD, Maxwell SRJ, Burrows G, Miller JP: Antioxidants, von Willebrand factor and endothelial cell injury in hypercholesterolaemia and vascular disease. Atherosclerosis 116:191-198, 1995.
13. Newman W, Beall LD, Carson CW, Hunder GG, Graben N, Randhawa ZI, Gopal TV, Weiner-Kronish J, Matthay MA: Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol 150:644-654, 1993.
14. Gearing AJH, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman SJ: Soluble forms of vascular adhesion molecules E-selectin, ICAM-1, VCAM-1: Pathological significance. Ann NY Acad Sci 667:324-331c, 1992.
15. Gearing AJH, Newman W: Circulating adhesion molecules in disease. Immunol Today 14:506-512, 1993.
16. Roberts WC: Atherosclerosis risk factors: Are there ten, or is there only one? Atherosclerosis 97:S5-S9, 1992.
17. Betteridge DJ, Broome K, Durrington PN, Mann JI, Miller JP, Neil HAW, Thompson GR, Thorogood M: Risk of fatal coronary heart disease in familial hypercholesterolaemia. Br Med J 303:893-896, 1991.
18. Blann AD, Bushell D, Davies A, Faragher EB, Miller JP, McCollum CN: von Willebrand factor, the endothelium and obesity. Int J Obesity 17:723-725, 1993.
19. Blann AD, McCollum CN: Adverse influence of cigarette smoking on the endothelium. Thromb Haemostas 70:707-711, 1993.
20. Altman DG: "Practical Statistics for Medical Research." London: Chapman and Hall, 1991.
21. Blann AD, McCollum CN: Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemostas 72:151-154, 1994.
22. Blann AD, Tse W, Maxwell SRJ, Waite MA: Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. J Hypertens 12:925-928, 1994.
23. Blann AD, Waite MA: von Willebrand factor and soluble E selectin in hypertension: Influence of treatment and value in predicting the progression of atherosclerosis. Coronary Artery Dis 7:143-147, 1996.
24. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G: Relation of serum lipoprotein(a) concentration and apoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolaemia. N Engl J Med 322:1494-1499, 1990.
25. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM: Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 74:758-765, 1986.
26. Mbewu AD, Bhatnagar D, Durrington PN, Hunt L, Ishola M, Arrol S, Mackness M, Lockley P, Miller JP: Serum lipoprotein (a) in patients heterozygous for familial hypercholesterolaemia their relatives and unrelated control populations. Arteriosclerosis Thrombosis 11:940-946, 1991.
27. Jauhianen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, Huttunen JK: Lipoprotein (a) and coronary disease risk: A nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 89:59-67, 1991.
28. Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PWF, Castelli WP, Schaefer EJ: Effects of age, sex, and menopausal status on plasma lipoprotein (a) levels: The Framingham Offspring Study. Circulation 87:1135-1141, 1993.
29. Blann AD, Jackson P, Bath PMW, Watts GF: von Willebrand factor, a possible indicator of endothelial cell damage, decreases during long-term compliance with a lipid-lowering diet. J Int Med 237:557-561, 1995.
30. Gralnick HR: von Willebrand's disease. In Ratnoff OD, Forbes CD (eds): "Disorders of Haemostasis." Philadelphia PA: Saunders, 1991, pp 203-244.
31. Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD: Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glucaemic control. Thromb Haemost 72:979-984, 1994.
32. Van Den Berg M, Boers GHJ, Franken DG, Blom HJ, van Kamp GJ, Jakobs C, Rauwerda JA, Kluft C, Stehouwer CDA: Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 25:176-181, 1995.
33. Smith FB, Lowe GDO, Fowkes FGR, Rumley A, Donnan PT, Housley E: Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease. Atherosclerosis 102: 155-162, 1993.
34. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Della Volpe A, Polli E, and the PLAT Study group: The PLAT study: Hemostatic function in relation to atherothrombotic ischaemic events in vascular disease patients. Arterio Thromb 12:1063-1070, 1992.
35. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK: Associations of factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis. Thromb Haemostas 70:380-385, 1993.
36. Wada H, Mori Y, Kaneko T, Wakita Y, Nakase T, Minamikawa K, Ohiwa M, Tamaki S, Tanigawa M, Kageyama S, Deguchi K, Nakano T, Shirakawa S, Suzuki K: Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolaemia. Am J Haematol 44:112-116, 1993.
37. Leake DS: Oxidised low density lipoproteins and atherogenesis. Br Heart J 69:476-478, 1993.
38. Witztum JL, Steinberg D: Role of oxidised low density lipoprotein in atherogenesis. J Clin Invest 88:1785-1792, 1991.
39. Hessler, JR, Robertson AL, Chisholm GM: LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscles and endothelial cells in culture. Atherosclerosis 32:213-219, 1979.
40. Blann AD, Midgley HS, Davis A, Burrows G: Oxidised lipoproteins are cytotoxic to endothelial cells in vitro. Thromb Haemostas 69:748 (abstract), 1993.
41. Thorne SA, Abbot SE, Winyard PG, Blake DR, Mills PG: Extent of oxidative modification of low density lipoprotein determines the degree of cytotoxicity to human coronary artery cells. Heart 75:11-16, 1996.
42. Penny WF, Weinstein M, Salzman EW, Ware JA: Correlation of circulating von Willebrand factor levels with cardiovascular hemodynamics. Circulation 83:1630-1636, 1991.
43. Flavahan NA: Atherosclerosis or lipoprotein-induced endothelial dysfunction: Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation 85:1927-1937, 1992.
44. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111-1115, 1992.
45. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P: The effect of cholesterol-lowering and antioxidant therapy on endothelium dependent coronary vasomotion. N Engl J Med 332:488-493, 1995.
46. Leung W-H, Lau C-P, Wong C-K: Beneficial effect of cholesterollowering therapy on coronary endothelium dependent relaxation in hypercholesterolaemic patients. Lancet 341:1496-1500, 1993.
47. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW: Hemostatic factors and therisk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332:635-641, 1995.
48. Jansson J-H, Nilsson TK, Johnson O: von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 66:351-355, 1991.
49. Sobel M, Bird KE, Tyler-Cross R, Marques D, Toma N, Conrad E, Harris RB: Heparins designed to specifically inhibit platelet interactions with von Willebrand factor. Circulation 93:992-999, 1996.
50. Ruggeri ZM: von Willebrand factor as a target for antithrombotic intervention. Circulation 86:111-26-111-29, 1992.
51. Dardik R, Ruggeri Z M, Savion N, Gitel S, Martinowitz U, Chu V, Varon D: Platelet aggregation on extracellular matrix: Effect of a recombinant GPIb-binding fragment of von Willebrand factor. Thromb Haemost 70:522-526, 1993.